Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 5/20 | 0.48 |
| ▸ | THRB | P10828 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17685745 | 0.96 | MGLL (0.49) | MGLLCNR1THRBALDH1A1MAPT | |
| SCHEMBL17685757 | 0.96 | MGLL (0.49) | MGLLCNR1THRBALDH1A1MAPT | |
| SCHEMBL16154807 | 0.96 | MGLL (0.49) | MGLLCNR1THRBALDH1A1MAPT | |
| SCHEMBL16154805 | 0.96 | MGLL (0.49) | MGLLCNR1THRBALDH1A1MAPT | |
| SCHEMBL16013040 | 0.95 | THRB (0.50) | MGLLCNR1THRBALDH1A1MAPT | |
| SCHEMBL16013041 | 0.95 | THRB (0.50) | MGLLCNR1THRBALDH1A1MAPT | |
| SCHEMBL16013481 | 0.92 | MGLL (0.51) | MGLLCNR1THRBALDH1A1MAPT | |
| SCHEMBL16013482 | 0.92 | MGLL (0.51) | MGLLCNR1THRBALDH1A1MAPT | |
| SCHEMBL19103562 | 0.92 | MGLL (0.51) | MGLLCNR1THRBALDH1A1MAPT | |
| SCHEMBL16013173 | 0.90 | ELANE (0.49) | MGLLCNR1THRBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | claimed |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-10-06 | — | — | US | disclosed |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-08-04 | — | — | US | disclosed |
| EP-2964608-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| EP-2964608-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-11-13 | — | — | US | disclosed |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-9504747-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2016-11-29 | — | — | US | disclosed |
| US-9504747-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2016-11-29 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20140303232-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20140303232-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | MGLL 28/4885CNR1 1158/4885THRB 3560/4885 |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | MGLL 28/4885CNR1 1158/4885THRB 3560/4885 |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | MGLL 28/4885CNR1 1158/4885THRB 3560/4885 |
| US-20140303232-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | MGLL 28/4885CNR1 1158/4885THRB 3560/4885 |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | MGLL 28/4885CNR1 1158/4885THRB 3560/4885 |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | MGLL 28/4885CNR1 1158/4885THRB 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.